Haemonetics
HAE
#2798
Rank
$4.45 B
Marketcap
$87.66
Share price
1.67%
Change (1 day)
5.44%
Change (1 year)

P/E ratio for Haemonetics (HAE)

P/E ratio as of April 2024 (TTM): 34.6

According to Haemonetics's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 34.6008. At the end of 2022 the company had a P/E ratio of 41.8.

P/E ratio history for Haemonetics from 2001 to 2023

PE ratio at the end of each year

Year P/E ratio Change
202241.8-65.87%
2021123120.82%
202055.5-24.18%
201973.2-34.55%
2018112-165.46%
2017-171-234.9%
2016127-487.6%
2015-32.7-151.15%
201463.910.27%
201357.921.76%
201247.6112.9%
201122.3-10.88%
201025.121.38%
200920.7-15.18%
200824.4-13.82%
200728.38.6%
200626.023.56%
200521.1-9.85%
200423.4-2.21%
200323.942.49%
200216.8-43.8%
200129.8

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
10.4-69.87%๐Ÿ‡บ๐Ÿ‡ธ USA
29.1-15.79%๐Ÿ‡ฎ๐Ÿ‡ช Ireland
37.3 7.72%๐Ÿ‡บ๐Ÿ‡ธ USA
7.86-77.29%๐Ÿ‡บ๐Ÿ‡ธ USA
41.5 20.02%๐Ÿ‡บ๐Ÿ‡ธ USA
49.5 43.08%๐Ÿ‡บ๐Ÿ‡ธ USA
15.0-56.74%๐Ÿ‡บ๐Ÿ‡ธ USA
-5.86-116.94%๐Ÿ‡บ๐Ÿ‡ธ USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.